Michael A. Briggs

GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer’s Disease Brain and Improves Cognitive Performance in Preclinical Models

Andrew D. Medhurst, A.R. Atkins, I.J.M. Beresford et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 300 citations

Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats

Andrew D. Medhurst, Michael A. Briggs, Gordon Bruton et al. · Biochemical Pharmacology · 2007 · 64 citations

Scopolamine-induced Memory Impairment, Medicine, Behavioural Pharmacology +7

Need for Cognition, Causal Processing, and Memory for Behavior

G. Daniel Lassiter, Michael A. Briggs, R. David Slaw · Personality and Social Psychology Bulletin · 1991 · 62 citations

Cognitive Science, Explicit Memory, Extensive Causal Processing +15

Need for Cognition and the Perception of Ongoing Behavior

G. Daniel Lassiter, Michael A. Briggs, Robert E. Bowman · Personality and Social Psychology Bulletin · 1991 · 61 citations

Behavioral Decision Making, Unitization Rate, Ongoing Behavior +17

Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole CB₂Agonist for the Treatment of Chronic Pain

Gerard M.P. Giblin, Andrew Billinton, Michael A. Briggs et al. · Journal of Medicinal Chemistry · 2009 · 53 citations · Full text